BC 3402
Alternative Names: BC-3402Latest Information Update: 18 Jun 2024
At a glance
- Originator Biocity Biopharmaceutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Liver cancer
- Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 05 Apr 2024 Efficacy, adverse events, pharmacokinetics and pharmacodynamcis data from a phase I trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 31 Oct 2023 Phase-I/II clinical trials in Liver cancer (Late-stage disease, Combination therapy) in China (IV) (NCT06111326)
- 01 Oct 2023 Biocity Biopharmaceutics plans a phase Ib/II trial for Liver cancer (Late-stage disease, Combination therapy) in China (IV, Infusion) (NCT06111326)